E-PROT-26
Ontology highlight
ABSTRACT:
TISSUE(S): Breast, Lymph Node
PROVIDER: E-PROT-26 | ExpressionAtlas | 2021-05-25
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-PROT-26-analysis-methods.tsv | Tabular | |||
| E-PROT-26-configuration.xml | Xml | |||
| E-PROT-26-factors.xml | Xml | |||
| E-PROT-26.condensed-sdrf.tsv | Tabular | |||
| E-PROT-26.idf.txt | Idf |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:Systems-wide profiling of breast cancer has so far built on RNA and DNA analysis by microarray and sequencing techniques. Dramatic developments in proteomic technologies now enable very deep profiling of clinical samples, with high identification and quantification accuracy. We analyzed 40 estrogen receptor positive (luminal), Her2 positive and triple negative breast tumors and reached a quantitative depth of more than 10,000 proteins. Comparison to mRNA classifiers revealed multiple discrepancies between proteins and mRNA markers of breast cancer subtypes. These proteomic profiles identified functional differences between breast cancer subtypes, related to energy metabolism, cell growth, mRNA translation and cell-cell communication. Furthermore, we derived a 19-protein predictive signature, which discriminates between the breast cancer subtypes, through Support Vector Machine (SVM)-based classification and feature selection. The deep proteome profiles also revealed novel features of breast cancer subtypes, which may be the basis for future development of subtype specific therapeutics.
2017-03-29 | MSV000080757 | MassIVE
Project description:Systems-wide profiling of breast cancer has so far built on RNA and DNA analysis by microarray and sequencing techniques. Dramatic developments in proteomic technologies now enable very deep profiling of clinical samples, with high identification and quantification accuracy. We analyzed 40 estrogen receptor positive (luminal), Her2 positive and triple negative breast tumors and reached a quantitative depth of more than 10,000 proteins. Comparison to mRNA classifiers revealed multiple discrepancies between proteins and mRNA markers of breast cancer subtypes. These proteomic profiles identified functional differences between breast cancer subtypes, related to energy metabolism, cell growth, mRNA translation and cell-cell communication. Furthermore, we derived a 19-protein predictive signature, which discriminates between the breast cancer subtypes, through Support Vector Machine (SVM)-based classification and feature selection. The deep proteome profiles also revealed novel features of breast cancer subtypes, which may be the basis for future development of subtype specific therapeutics.
2016-01-05 | PXD002619 | Pride
Project description:Urinary extracellular vesicles (uEVs) reflect the biological conditions of the producing cells, and can allows us to better understand cancer progression. We have, herein, aimed at quantifying the concentration and at generating the proteomic profile of uEVs in breast cancer (BC) patients as compared to that of healthy controls (CT). The proteomic profiling of the uEVs was facilitated through LC-MS/MS.
2023-12-31 | PXD039122 | JPOST Repository
Project description:Systems-wide quantitative proteomic study of breast cancer tumours
2021-05-25 | E-PROT-27 | ExpressionAtlas
Project description:MicroRNAs expression profiling during breast cancer progression
| PRJNA169159 | ENA
Project description:Metastatic (as well as tumor) microenvironments contain both cancer-promoting as well as cancer restraining factors. The balance between these opposing forces determines the fate of cancer cells that disseminate to secondary organ sites. In search for microenvironmental drivers or inhibitors of metastasis, we identified, in a previous study, the beta subunit of hemoglobin (HBB) as a lung-derived antimetastatic factor. In the present study, exploring mechanisms leading to melanoma brain metastasis, we discovered that brain-derived factors restrain proliferation and induce apoptosis and necrosis of brain-metastasizing melanoma cells. Employing various purification procedures, we identified a heterodimer composed of hemoglobin alpha and beta chains that performs these anti-metastatic functions. Neither the alpha nor the beta subunit alone were inhibitory. An alpha/beta chain dimer chemically purified from human hemoglobin inhibited the cell viability of primary melanomas, melanoma brain metastasis (MBM), and breast cancer cell lines. The dimer-induced DNA damage, cell cycle arrest at the SubG1 phase, apoptosis, and significant necrosis in four MBM cell lines. Proteomic analysis of dimer-treated MBM cells revealed that the dimer downregulates the expression of BRD4, GAB2, and IRS2 proteins playing crucial roles in cancer cell sustainability and progression.
2023-03-08 | GSE225459 | GEO
Project description:Formalin-fixed paraffin-embedded (FFPE) samples are valuable archived bio-specimens of individuals and are commonly used in biomedical research. In this study, we present a rapid, highly sensitive, and reproducible protocol for deep proteomic profiling of FFPE specimens using a spectral library-free approach. This method is applicable for high-throughput proteomic profiling and can be used on various types of specimens. Gene ontology (GO) and functional analysis specifically enriched pathways associated with brain and breast cancer, demonstrating the sensitivity and specificity of the protocol.
2023-03-08 | MSV000091446 | MassIVE
Project description:The objective of this microarray study was to obtain whole genome gene expression data from breast cancer, human to mouse xenograft models and from the primary cancer used for the xenograft, when possible. We also profiled these xenograft breast cancer tumors as they were passaged into additional mice. Whole Genome expression data allows us to monitor gene expression conservation and/or changes that occur from human to mouse, and from the initial mouse graft through subsequent passages. PAM50 molecular subtypes are also processed using the expression data. The xenografts provide in-vivo models for functional and therapeutic studies.
2013-10-10 | GSE41685 | GEO
Project description:Integrative proteomic profiling of ovarian cancer cell lines
2021-05-25 | E-PROT-28 | ExpressionAtlas
Project description:Deep proteomic evaluation of primary and cell line motoneuron disease models delineates major differences in neuronal characteristics
2022-01-14 | E-PROT-12 | ExpressionAtlas